Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulin inhalers as good as injections, say firms

This article was originally published in Clinica

Executive Summary

Rival companies developing insulin inhalers for the noninvasive treatment of Type II diabetes have reported strong trial results for their respective devices, which are designed to avoid the pain and inconvenience of daily injections. Aerogen is confident about its hand-held Aerodose inhaler, while Aradigm has its hopes pinned on its AERx electronic insulin delivery system. Both devices could in time be achieving a share the US 17m diabetic patients' market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel